



Infant and High-Risk Children RSV Prevention Program

Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract illness in infants and young children and can result in serious illness and hospitalization. Immunization is an important way to protect infants from severe RSV disease. Ontario's RSV prevention program offers two publicly funded options: **Beyfortus® (nirsevimab)** administered to eligible infants and high-risk children, and **Abrysvo® (RSVpreF)**, administered during pregnancy.

Beyfortus® (Nirsevimab) – Infants and Children

Beyfortus® is publicly funded for infants and children who meet any one of the following criteria:

- Infants born April 1 or after, and less than 8 months of age at time of immunization.
- Children less than 24 months of age who are vulnerable to severe RSV disease, following a discussion with their pediatric specialist including children with:
 - Chronic lung disease (CLD), including bronchopulmonary dysplasia (BPD), defined by need for ongoing respiratory support and supplemental oxygen therapy at 36 weeks postmenstrual age (gestational age at birth plus chronological age) or discharged home, if earlier.
 - Hemodynamically significant cyanotic or acyanotic congenital heart disease (CHD) defined as infants requiring corrective surgery or are on cardiac medication for congestive heart failure or diagnosed with moderate to severe pulmonary hypertension.
 - Severe immunodeficiency.
 - Down syndrome/Trisomy 21.
 - Cystic fibrosis with recurrent pulmonary exacerbations requiring hospitalization, deteriorating pulmonary function and/or severe growth delay.
 - Neuromuscular disease impairing clearing of respiratory secretions.
 - Severe congenital airway anomalies impairing the clearing of respiratory secretions.

Note: Children who were less than 12 months of age and approved for coverage in the previous RSV season for chronic lung disease and bronchopulmonary dysplasia remain eligible, irrespective of their clinical status in the second RSV season.

over...

Beyfortus® Administration Guidelines for Infants and Children

Category	Weight	Dose	Timing
Infants born during the current RSV season	Less than 5 kg	50 mg in 0.5 mL (100 mg/mL)	Administered from birth
	Greater than or equal to 5 kg	100 mg in 1 mL (100 mg/mL)	Administered from birth
Infants born April 1 or after and less than 8 months of age at the time of administration	Less than 5 kg	50 mg in 0.5 mL (100 mg/mL)	Shortly before or during RSV season*
	Greater than or equal to 5 kg	100 mg in 1 mL (100 mg/mL)	Shortly before or during RSV season*
Children over 8 months and less than 24 months of age and at continued high-risk from RSV infection	N/A	200 mg (two 1 mL injections of 100 mg/mL)*	Shortly before or during RSV season*

*Due to the seasonality of the RSV virus, Beyfortus® should be administered shortly before and during the active RSV season. Beyfortus® should be offered to eligible infants and children beginning October 1 each year, based on specific timing of product availability and throughout the RSV season.

**If a child weighs less than 10 kg entering their second RSV season, consideration can be given to administering a single dose of 100 mg at the clinical discretion of the provider.

Abrysvo® (RSVpreF) – Pregnant Individuals

Abrysvo® is publicly funded for pregnant individuals between **28-36** weeks gestation who are expected to deliver during the RSV season following a discussion with a health care provider (HCP).

Abrysvo® is authorized by Health Canada from 32-36 weeks gestation. The National Advisory Committee on Immunization (NACI) recommends that it may be administered from 28-36 weeks. **Administration before 32 weeks is off-label and is subject to the sole clinical judgment of the HCP.** There is currently no evidence on repeat vaccination with Abrysvo® in subsequent pregnancies. For subsequent pregnancies, HCPs should consider Beyfortus® for the infant after birth.

Administration of both Abrysvo® during pregnancy and Beyfortus® to the infant is NOT routinely recommended, except in the following circumstances:

- Infants born less than 14 days after Abrysvo® was administered during pregnancy OR
- Infants at increased risk of severe RSV disease, including all premature infants (less than 37 weeks' gestation) and infants who meet any of the high-risk criteria above.

Ordering & New Physician Billing Code

Place orders using the [Seasonal Respiratory Vaccine Order Form](#) (durham.ca/hcp > Forms > Order).

New for the 2026-27 season: Use fee code **G849** for publicly funded RSV immunization products administered in primary care to support accurate capture of RSV administration data.

For further information, **including eligibility and Health Care Provider Fact Sheets**, visit durham.ca/hcp (Respiratory illnesses > Respiratory Syncytial Virus (RSV) > Resources).

October 02, 2026

905-668-2020 or 1-800-841-2729 | durham.ca/health

If you require this information in an accessible format, contact 1-800-841-2729.

